Drug Profile
Exaluren - Eloxx Pharmaceuticals
Alternative Names: ELX-02; NB-124; Synthetic aminoglycosideLatest Information Update: 16 Nov 2023
Price :
$50
*
At a glance
- Originator Technion - Israel Institute of Technology
- Developer Eloxx Pharmaceuticals
- Class Amines; Aminoglycosides; Antifibrotics; Small molecules
- Mechanism of Action Ribosomal protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystinosis; Hereditary nephritis
- Preclinical Cystic fibrosis
- No development reported Duchenne muscular dystrophy; Mucopolysaccharidosis I; Rett syndrome